- Stocks
- Healthcare
- NASDAQ: EXEL

Price (delayed)

$20.695

Market cap

$6.52B

P/E Ratio

66.76

Dividend/share

N/A

EPS

$0.31

Enterprise value

$6.08B

Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work

The revenue has grown by 16% YoY and by 12% from the previous quarter

The gross profit has grown by 15% YoY and by 12% from the previous quarter

The company's net income has shrunk by 67% YoY but it rose by 45% QoQ

The company's EPS has shrunk by 66% YoY but it rose by 41% QoQ

EXEL's quick ratio is down by 36% year-on-year and by 7% since the previous quarter

The debt has increased by 10% YoY

What are the main financial stats of EXEL

Market
Valuations
Earnings

Shares outstanding

315.05M

Market cap

$6.52B

Enterprise value

$6.08B

Price to earnings (P/E)

66.76

Price to book (P/B)

3.17

Price to sales (P/S)

5.62

EV/EBIT

53.82

EV/EBITDA

46.89

EV/Sales

5.26

Revenue

$1.16B

EBIT

$112.98M

EBITDA

$129.67M

Free cash flow

$218.09M

Per share
Balance sheet
Liquidity

EPS

$0.31

Free cash flow per share

$0.69

Book value per share

$6.52

Revenue per share

$3.68

TBVPS

$7.33

Total assets

$2.37B

Total liabilities

$324.19M

Debt

$53.22M

Equity

$2.04B

Working capital

$1.34B

Debt to equity

0.03

Current ratio

6.24

Quick ratio

5.95

Net debt/EBITDA

-3.39

Margins
Efficiency
Dividend

EBITDA margin

11.2%

Gross margin

96%

Net margin

8.1%

Operating margin

8.7%

Return on assets

4.3%

Return on equity

4.9%

Return on invested capital

7.1%

Return on capital employed

5.3%

Return on sales

9.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Exelixis stock price performed over time

Intraday

1.7%

1 week

4.41%

1 month

6.51%

1 year

-13.19%

YTD

3.11%

QTD

13.58%

How have Exelixis's revenue and profit performed over time

Revenue

$1.16B

Gross profit

$1.11B

Operating income

$100.12M

Net income

$94.04M

Gross margin

96%

Net margin

8.1%

Exelixis's operating income has surged by 90% QoQ but it has shrunk by 69% YoY

EXEL's operating margin has dropped by 73% year-on-year but it has surged by 71% since the previous quarter

The net margin has plunged by 71% YoY but it has increased by 29% from the previous quarter

The company's net income has shrunk by 67% YoY but it rose by 45% QoQ

What is Exelixis's growth rate over time

What is Exelixis stock price valuation

P/E

66.76

P/B

3.17

P/S

5.62

EV/EBIT

53.82

EV/EBITDA

46.89

EV/Sales

5.26

The company's EPS has shrunk by 66% YoY but it rose by 41% QoQ

The P/E is 13% below the 5-year quarterly average of 75.1

EXEL's P/B is 83% below its 5-year quarterly average of 18.4 and 11% below its last 4 quarters average of 3.5

The company's equity rose by 11% YoY and by 7% QoQ

EXEL's price to sales (P/S) is 52% lower than its 5-year quarterly average of 11.5 and 15% lower than its last 4 quarters average of 6.5

The revenue has grown by 16% YoY and by 12% from the previous quarter

How efficient is Exelixis business performance

The company's return on sales has shrunk by 72% YoY but it rose by 46% QoQ

The ROA has plunged by 71% YoY but it has grown by 39% from the previous quarter

The ROIC has plunged by 71% YoY but it has soared by 58% from the previous quarter

The company's return on equity has shrunk by 70% YoY but it rose by 40% QoQ

What is EXEL's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EXEL.

How did Exelixis financials performed over time

EXEL's total liabilities has surged by 52% year-on-year and by 16% since the previous quarter

EXEL's current ratio is down by 36% year-on-year and by 7% since the previous quarter

The debt is 97% less than the equity

The company's equity rose by 11% YoY and by 7% QoQ

The debt has increased by 10% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.